期刊文献+

微球载药系统的前沿进展和临床转化 被引量:1

Advances and clinical transformation of microsphere drug delivery systems
原文传递
导出
摘要 微球载药系统具有药物缓释和控释功能,可提高药物稳定性,临床应用前景广阔,已成为创新制剂开发的前沿和热点领域。近年来,科研人员发展了基于乳化溶剂挥发、高压均质、膜乳化和微流控等技术平台的载药微球制备方法,并将微球载药系统应用于恶性肿瘤、精神分裂症、神经退行性疾病等重大疾病的临床治疗,取得了良好的经济和社会效益。本文系统总结了微球载药系统的制备方法和临床应用情况,同时讨论了新型微球载药系统临床转化方面的挑战,希望进一步推动微球载药系统的开发和临床转化。 The microsphere drug delivery systems have been extensively exploited for providing controllable drug release kinetics,enhancing drug stability and localized drug delivery.In past decade,dozens of microsphere drug delivery systems have been developed for clinical therapy of cancer,schizophrenia and neurodegenerative diseases(e.g.,Alzheimer's disease and Parkinsonism).In this review article,we comprehensively summarized the fabrication methods of drug delivery systems and highlighted their advances for clinical application.Furthermore,we analyzed the potential and the challenges for clinical translation of the drug delivery systems.
作者 吴其泷 兰文悦 崔明杰 王珺珏 程文豪 于海军 WU Qi-long;LAN Wen-yue;CUI Ming-jie;WANG Jun-jue;CHENG Wen-hao;YU Hai-jun(Nanjing University of Chinese Medicine,Nanjing 210023,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shenyang Pharmaceutical University,Shenyang 110016,China;University of Chinese Academy of Sciences,Beijing 100049,China)
出处 《药学学报》 CAS CSCD 北大核心 2024年第12期3242-3250,共9页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(U22A20328) 上海市科委基础研究面上项目(23ZR1475000)。
关键词 微球载药系统 制备方法 局部药物递送 药物储库 临床转化 microsphere drug delivery system fabrication method localized drug delivery drug deposit clinical translation
作者简介 通讯作者:于海军,Tel:86-21-68077900,E-mail:hjyu@simm.ac.cn。
  • 相关文献

参考文献17

二级参考文献203

  • 1王襄平,梅兴国.乳酸/羟基乙酸共聚物的分子量及其单体组成比例对利培酮微球性质的影响[J].中国药房,2007,18(1):38-41. 被引量:13
  • 2郁晓,任杰,任天斌,袁华.两性霉素B缓释微球的制备及缓释性能研究[J].中国生物医学工程学报,2007,26(3):445-451. 被引量:10
  • 3Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-917.
  • 4De Lope, C. R., S. Tremosini, et al. Management of HCC[J]. J Hepatol, 2012, 56(Suppl 1): S75-87.
  • 5Lencioni R, Crocetti L, De Simone P, et al. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects [J] Transpl Int, 2010, 23(7): 698-703.
  • 6Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective[J]. Jpn J Clin Oncol, 2012, 42 (4): 247-55.
  • 7Lencioni, R. Loco-regional treatment of hepatocellular carcinoma [J]. Hepatology, 2010, 52(2): 762-73.
  • 8Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics[J]. J Hepatol, 2007, 46(3): 474-81.
  • 9Yu JS, Kim KW, Jeong MG, et al. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy[J]. Cardiovasc lntervent Radiol, 2002, 25(4): 270-4.
  • 10Chung J, Yu JS, Chung JJ, et al. Haemodynamic events and localised parenchymal changes following transeatheter arterial chemoembolisation for hepatic malignancy: interpretation of imaging findings[J]. Br J Radiol, 2010, 83(985): 71-81.

共引文献1300

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部